Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
25.12
+0.62 (2.53%)
Apr 13, 2026, 4:00 PM EDT - Market closed
Immunovant Employees
Immunovant had 362 employees as of March 31, 2025. The number of employees increased by 155 or 74.88% compared to the previous year.
Employees
362
Change (1Y)
155
Growth (1Y)
74.88%
Revenue / Employee
n/a
Profits / Employee
-$1,282,318
Market Cap
5.11B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 362 | 155 | 74.88% |
| Mar 31, 2024 | 207 | 43 | 26.22% |
| Mar 31, 2023 | 164 | 40 | 32.26% |
| Mar 31, 2022 | 124 | 56 | 82.35% |
| Mar 31, 2021 | 68 | 26 | 61.90% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| CG Oncology | 142 |
IMVT News
- 12 days ago - Immunovant's treatment for eye disease fails late-stage trial - Reuters
- 2 months ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 - GlobeNewsWire
- 2 months ago - Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - GlobeNewsWire
- 4 months ago - Immunovant Announces Pricing of $550 Million Common Stock Financing - GlobeNewsWire
- 5 months ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 - GlobeNewsWire
- 6 months ago - Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - GlobeNewsWire
- 7 months ago - Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - GlobeNewsWire
- 8 months ago - IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm - Business Wire